<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933933</url>
  </required_header>
  <id_info>
    <org_study_id>7B5-02-06R01</org_study_id>
    <nct_id>NCT00933933</nct_id>
  </id_info>
  <brief_title>Evaluation of Diagnostic HIV Ag/Ab Combo Assay</brief_title>
  <official_title>Evaluation of ARCHITECT HIV Ag/Ab Combo Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Diagnostics Division</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Diagnostics Division</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test blood specimens using a new investigational test that detects antigen and antibody to
      human immunodeficiency virus (HIV). Results will be compared to an approved HIV antibody test
      and supplemental testing performed to determine HIV status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All specimens collected under separate specimen collection protocols or obtained from
      specimen suppliers will be provided to the clinical sites performing the investigational HIV
      test.

      This includes 6252 specimens collected from normal healthy individuals (7B5-02-05Z01-01:
      Collection of Specimens Used in Abbott Laboratories In Vitro Diagnostic HIV and Hepatitis
      Assays Clinical Studies)and from specimen suppliers. 588 specimens from HIV-infected
      pediatric subjects and 448 pregnant females at risk for HIV infection collected under
      protocol (7B5-02-05Z01-02: Collection of Pediatric and Pregnant Female Specimens Used in the
      Abbott Laboratories In Vitro Diagnostic HIV Assay)and from specimen suppliers. All specimens
      were previously collected and frozen, except for a subset of 586 specimens from normal
      healthy population and 55 specimen from pregnant females at risk for HIV infection which were
      collected under separate specimen collection protocols and tested as fresh specimens during
      the study.

      In addition, 83 specimens that were HIV antigen positive, 1121 specimens that were HIV-1
      antibody positive, 201 specimens that were HIV-2 antibody positive, and 1409 specimens from
      US at risk for HIV infection or from HIV-2 endemic area were all obtained from specimen
      suppliers, except for 11 pediatric specimens collected under a separate protocol
      (7B5-02-05Z01-02: Collection of Pediatric and Pregnant Female Specimens Used in the Abbott
      Laboratories In Vitro Diagnostic HIV Assay).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection</measure>
    <time_frame>3 months</time_frame>
    <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Architect HIV Combo Test Data for Clinical Sensitivity in HIV Positive Specimens</measure>
    <time_frame>3 months</time_frame>
    <description>Positive HIV status was determined by the results of the HIV-1 Western blot, HIV-2 Western blot, and/or HIV-1 ribonucleic acid (RNA) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Architect HIV Combo Test Data for Specificity and Sensitivity in Pregnant Female Population</measure>
    <time_frame>3 months</time_frame>
    <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Architect HIV Combo Test Data for Specificity and Sensitivity in Pediatric Population (From 2 up to 21 Years of Age)</measure>
    <time_frame>3 months</time_frame>
    <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Architect HIV Combo Test Data for Reactivity of Architect HIV Combo in Increased HIV Risk Populations</measure>
    <time_frame>3 months</time_frame>
    <description>Reactivity was determined by the results of the Architect HIV Ag/Ab Combo assay and supplemental testing by HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">635</enrollment>
  <condition>Human Immunodeficiency Viruses</condition>
  <arm_group>
    <arm_group_label>ARCHITECT HIV Ag/Ab Combo Specificity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specimens collected from normal apparently healthy individuals at low risk for HIV infection will be tested by the investigational HIV test and FDA-licensed HIV test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARCHITECT HIV Ag/Ab Combo Sensitivity</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Specimen with confirmed positive HIV Antigen, HIV-1 antibody, or HIV-2 antibody will be tested by the investigational HIV test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARCHITECT HIV Ag/Ab Combo Reactivity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specimen collected from individuals at risk for HIV infection will be tested by the investigational HIV test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARCHITECT HIV Ag/Ab Combo</intervention_name>
    <description>Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.</description>
    <arm_group_label>ARCHITECT HIV Ag/Ab Combo Specificity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARCHITECT HIV Ag/Ab Combo</intervention_name>
    <description>Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.</description>
    <arm_group_label>ARCHITECT HIV Ag/Ab Combo Reactivity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Normal Healthy Population:

        Inclusion Criteria:

          -  Apparently healthy individual at the time of enrollment as affirmed by the subject

        Exclusion Criteria:

          -  HIV infection as affirmed by the subject

        Pregnant Female Population at Risk for HIV Infection:

        Inclusion Criteria:

          -  Subject is a pregnant female

          -  Subject has risk factor for HIV infection

        Exclusion Criteria:

          -  HIV infection as affirmed by the subject

        HIV-1 Positive Pregnant Female Subjects

        Inclusion Criteria:

          -  Subject is a pregnant female in first, second, or third trimester

          -  Subject must have documented HIV infection

        Exclusion Criteria:

        HIV-1 Positive Pediatric Subjects

        Inclusion Criteria:

          -  Subject must be 2 years to 16 years of age

          -  Subject must have documented HIV infection (e.g., Western blot positive or HIV RNA
             positive/detectable)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Roberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ARUP Laboratories</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence Demers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Apple, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Medical Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Loeffelholz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical Branch at Galveston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Heffner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clement J. Zablocki VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinellas County Health Dept, Florida Department of Health</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Clinic, LLP</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Medical Research Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John T. Mather Memorial Hospital</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>117777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Houston and Southeast Texas, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARUP Laboratories</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108-1221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Research Specialists, LLC</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clement J. Zablocki VA Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2009</study_first_posted>
  <results_first_submitted>July 19, 2010</results_first_submitted>
  <results_first_submitted_qc>July 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2010</results_first_posted>
  <last_update_submitted>July 5, 2011</last_update_submitted>
  <last_update_submitted_qc>July 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Barbara Kaesdorf, Clinical Project Manager</name_title>
    <organization>Abbott Diagnostics Division</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All specimens collected under separate collection protocols or obtained from specimen suppliers: human immunodeficiency virus (HIV) antigen positive samples, HIV-1 antibody positive, specimens collected from individuals at risk for HIV infection in the United States (US), HIV-2 antibody positive and specimens collected from HIV-2 endemic area.</recruitment_details>
      <pre_assignment_details>All subjects were assigned to one group. There was no pre-screening criteria for this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Architect HIV Ag/Ab Combo Specificity</title>
          <description>Specificity populations included:
6164 specimens collected from apparently healthy individuals at low risk for HIV infection (16-89 years of age) which includes 250 specimens from pregnant females in first trimester of pregnancy.
448 specimen from presumed HIV negative pregnant females from 16 to 44 years of age.
588 specimen from pediatric presumed negative for HIV from 2 to 21 years of age.
Specimens were collected under separate collection protocols or by specimens vendors and tested with investigation HIV test.</description>
        </group>
        <group group_id="P2">
          <title>Architect HIV Ag/Ab Combo Sensitivity</title>
          <description>Sensitivity populations included:
1287 specimens or commercial panel members HIV-1 p24 Antigen positive, specimens confirmed HIV-1 antibody positive and specimens confirmed HIV-2 antibody positive.
67 specimens from pregnant females from all three trimesters confirmed HIV posiitve by supplemental testing.
64 specimens from pediatric subjects confirmed HIV positive by supplemental testing (2 to 21 years of age).
Specimens were collected under separate collection protocols or by specimens vendors and tested with investigational HIV test.</description>
        </group>
        <group group_id="P3">
          <title>Architect HIV Ag/Ab Combo Reactivity</title>
          <description>Reactivty populations included:
1206 specimens collected from individuals at increased risk for HIV infection (16-89 years of age) from US and Cote D'Ivoire.
203 specimen from pregnant females at risk for HIV infection.
Of these 1409 specimens, 61 were collected from individual that were from 16 up to 21 years of age.
Specimens were collected under separate collection protocols or by specimens vendors and tested with investigation HIV test.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>General Population From 16 to 89 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6164"/>
                <participants group_id="P2" count="1287"/>
                <participants group_id="P3" count="1206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6164"/>
                <participants group_id="P2" count="1267"/>
                <participants group_id="P3" count="1206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet criteria for analysis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Pregnant Females Between 16-44 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Specimens classified incorrectly</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Pediatric From 2 to 21 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="588"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="0">Specimens from individuals 16-21 years included reactivity for general population or pregnant women.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="588"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="0">Specimens from individuals 16-21 years included reactivity for general population or pregnant women</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Architect HIV Ag/Ab Combo Specificity</title>
          <description>Specimens collected from apparently healthy individuals under a separate specimen collection protocol (7B5-02-05Z01-01) or obtained from specimen vendors and were tested with investigational HIV test.</description>
        </group>
        <group group_id="B2">
          <title>Architect HIV Ag/Ab Combo HIV-1 Antigen Sensitivity</title>
          <description>Specimens obtained from specimen vendors were tested with investigational HIV test.</description>
        </group>
        <group group_id="B3">
          <title>Architect Ag/Ab Combo HIV-1 Antibody Sensitivity</title>
          <description>Specimens collected from HIV-1 infected individuals under a separate specimen collection protocol (pediatric subjects 7B5-02-05Z01-02) or obtained from specimen vendors and were tested with investigational HIV test.</description>
        </group>
        <group group_id="B4">
          <title>Architect HIV Ag/Ab Combo HIV-2 Antibody Sensitivity</title>
          <description>Specimens obtained from specimen vendors were tested with investigational HIV test.</description>
        </group>
        <group group_id="B5">
          <title>Architect HIV Ag/Ab Combo Reactivity</title>
          <description>Specimens collected from individuals at increased risk for HIV infection under a separate specimen collection protocol (pregant females 7B5-02-05Z01-02) or obtained from specimen vendors and were tested with investigational HIV test.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6252"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="1121"/>
            <count group_id="B4" value="201"/>
            <count group_id="B5" value="1409"/>
            <count group_id="B6" value="9066"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>between 2 and 21 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="588"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 21 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5663"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1057"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1304"/>
                    <measurement group_id="B6" value="8024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="201"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4165"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="231"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="530"/>
                    <measurement group_id="B6" value="4926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2087"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="890"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="879"/>
                    <measurement group_id="B6" value="3856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="201"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6252"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="1121"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="896"/>
                    <measurement group_id="B6" value="8347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CÃ´te D'Ivoire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="201"/>
                    <measurement group_id="B5" value="513"/>
                    <measurement group_id="B6" value="714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cameroon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection</title>
        <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
        <time_frame>3 months</time_frame>
        <population>Specificity determined from 6,164 specimens from apparently healthy individuals (low risk): includes 250 specimens from pregnant females in first trimester and 580 specimens from low risk population prospectively collected and tested fresh during study. Total of 37 confirmed HIV positives by supplemental testing were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Architect HIV Ag/Ab Specificity - Low Risk for HIV Infection</title>
            <description>Specimens collected from a population of apparently healthy individuals at low risk for HIV infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection</title>
          <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
          <population>Specificity determined from 6,164 specimens from apparently healthy individuals (low risk): includes 250 specimens from pregnant females in first trimester and 580 specimens from low risk population prospectively collected and tested fresh during study. Total of 37 confirmed HIV positives by supplemental testing were excluded from analysis.</population>
          <units>Blood Specimens</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HIV Ag/Ab Combo Reactive, HIV status Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="99.62" upper_limit="99.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Reactive, HIV status Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Nonreactive HIV status Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Nonreactive HIV status Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Specificity</param_type>
            <param_value>99.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.62</ci_lower_limit>
            <ci_upper_limit>99.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Architect HIV Combo Test Data for Clinical Sensitivity in HIV Positive Specimens</title>
        <description>Positive HIV status was determined by the results of the HIV-1 Western blot, HIV-2 Western blot, and/or HIV-1 ribonucleic acid (RNA) test.</description>
        <time_frame>3 months</time_frame>
        <population>Sensitivity was determine using confirmed positive specimens/panels for HIV-1 Antigen (63 samples/panels/viral isolates), HIV-1 antibody (1003 US population) and HIV-2 antibody (201 endemic area of Ivory Coast) based on supplemental testing.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV p24 Antgen Sensitivity</title>
            <description>HIV-1 Antigen positive specimens/commercial panel members (HIV Westerm blot negative and confirmed positive by HIV-1 p24 Antigen and/or HIV RNA) and HIV-1 viral isolates.</description>
          </group>
          <group group_id="O2">
            <title>HIV-1 Antibody Sensitivity</title>
            <description>Specimens collected from HIV infected individuals in US population confirmed by HIV-1 Western blot.</description>
          </group>
          <group group_id="O3">
            <title>HIV-2 Antibody Sensitivity</title>
            <description>Specimens collected from HIV infected individuals in Ivory Coast confirmed by HIV-2 Western blot.</description>
          </group>
        </group_list>
        <measure>
          <title>Architect HIV Combo Test Data for Clinical Sensitivity in HIV Positive Specimens</title>
          <description>Positive HIV status was determined by the results of the HIV-1 Western blot, HIV-2 Western blot, and/or HIV-1 ribonucleic acid (RNA) test.</description>
          <population>Sensitivity was determine using confirmed positive specimens/panels for HIV-1 Antigen (63 samples/panels/viral isolates), HIV-1 antibody (1003 US population) and HIV-2 antibody (201 endemic area of Ivory Coast) based on supplemental testing.</population>
          <units>Blood specimens</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="1003"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ARCHITECT HIV Ag/Ab Reactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="1003"/>
                    <measurement group_id="O3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARCHITECT HIV Ag/Ab Nonreactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Sensitivity</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.31</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Sensitivity</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.63</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Sensitivity</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.18</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Architect HIV Combo Test Data for Specificity and Sensitivity in Pregnant Female Population</title>
        <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
        <time_frame>3 months</time_frame>
        <population>HIV negative status determined for specimens reactive by investigational assay and/or comparator by supplemental testing algorithm including HIV-1 Western blot, HIV-2 enzyme immunoassay (EIA), HIV-2 Western blot, HIV-1 p24 Antigen assay and HIV-1 RNA. HIV positive status determined by HIV-1 Western blot. Specimens from pregnant females.</population>
        <group_list>
          <group group_id="O1">
            <title>Architect HIV Ag/Ab Combo Specificity in Pregnant Females</title>
            <description>HIV presumed negative specimens from pregnant females tested with investigation HIV test, comparator assay and supplemental tests.</description>
          </group>
          <group group_id="O2">
            <title>Architect HIV Ag/Ab Combo Sensitivity in Pregnant Females</title>
            <description>HIV confirmed positive specimens from pregnant females tested with investigation HIV test, comparator assay and supplement tests.</description>
          </group>
        </group_list>
        <measure>
          <title>Architect HIV Combo Test Data for Specificity and Sensitivity in Pregnant Female Population</title>
          <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
          <population>HIV negative status determined for specimens reactive by investigational assay and/or comparator by supplemental testing algorithm including HIV-1 Western blot, HIV-2 enzyme immunoassay (EIA), HIV-2 Western blot, HIV-1 p24 Antigen assay and HIV-1 RNA. HIV positive status determined by HIV-1 Western blot. Specimens from pregnant females.</population>
          <units>Blood specimens</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Architect HIV Ag/Ab Reactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Architect HIV Ag/Ab Nonreactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Specificity</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.18</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Sensitivity</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.48</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Architect HIV Combo Test Data for Specificity and Sensitivity in Pediatric Population (From 2 up to 21 Years of Age)</title>
        <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
        <time_frame>3 months</time_frame>
        <population>Specificity determine from 588 specimens: 364 low risk, 95 increased risk, 47 increased risk (HIV-2 endemic area), 44 pregnant females low risk and 38 pregnant females increased risk with HIV negative status. Sensitivity determined from 65 specimens: 60 HIV-1 infected, 2 HIV-1 infected pregnant females, 2 HIV infected from HIV-2 endemic area.</population>
        <group_list>
          <group group_id="O1">
            <title>Architect HIV Ag/Ab Combo Specificity in Pediatric Population</title>
            <description>Specimens presumed HIV negative tested with investigational HIV test, FDA-licensed comparator assay and supplemental tests. Specimens from individuals between 2 and 21 years of age.</description>
          </group>
          <group group_id="O2">
            <title>Architect HIV Ag/Ab Combo Sensitivity in Pediatric Population</title>
            <description>Specimens confirmed HIV positive by HIV-1 Western blot were tested with investigational HIV test. Specimens from individuals between 2 and 21 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Architect HIV Combo Test Data for Specificity and Sensitivity in Pediatric Population (From 2 up to 21 Years of Age)</title>
          <description>HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
          <population>Specificity determine from 588 specimens: 364 low risk, 95 increased risk, 47 increased risk (HIV-2 endemic area), 44 pregnant females low risk and 38 pregnant females increased risk with HIV negative status. Sensitivity determined from 65 specimens: 60 HIV-1 infected, 2 HIV-1 infected pregnant females, 2 HIV infected from HIV-2 endemic area.</population>
          <units>Blood specimens</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HIV Ag/Ab Combo Reactive HIV Status Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Reactive HIV Status Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Nonreactive HIV Status Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Nonreactive HIV Status Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Specificity</param_type>
            <param_value>99.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.06</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Sensitivity</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.40</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Architect HIV Combo Test Data for Reactivity of Architect HIV Combo in Increased HIV Risk Populations</title>
        <description>Reactivity was determined by the results of the Architect HIV Ag/Ab Combo assay and supplemental testing by HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
        <time_frame>3 months</time_frame>
        <population>Final HIV status determined for specimens reactive by investigational assay and/or comparator by supplement testing algorithm. Supplemental testing involved HIV-1 Western blot, HIV-2 EIA, HIV-2 Western blot, HIV-1 p24 Antigen assay and HIV-1 RNA. HIV positive status determined by HIV-1 Western blot.</population>
        <group_list>
          <group group_id="O1">
            <title>Increased Risk for HIV in US Population</title>
            <description>Specimens collected from 693 individuals in the US population documented as having one or more of the following risk factors: users of injecting drugs, unprotected sex with someone who is infected with HIV, diagnosed or treated for a sexually transmitted disease (STD), hepatitis or tuberculosis, multiple sex partners, men who have sex with men, men who have sex with men and are users of injecting drugs, unprotected sex with someone who has been diagnosed or treated for an STD, risk factor not identified but requested an HIV test. Specimens obtained from specimen vendors and were tested with investigational HIV test.</description>
          </group>
          <group group_id="O2">
            <title>Increased Risk for HIV From HIV-2 Endemic Area</title>
            <description>Specimens from 513 individuals documented as being at risk for acquiring HIV that reside in an HIV-2 endemic area (Cote De'Ivoire) having one or more of the following risk factors: unprotected sex with someone who is infected with HIV, multiple sex partners, men who have sex with men, users of injecting drugs. Specimens were obtained from specimen vendors and tested with investigational HIV test.</description>
          </group>
          <group group_id="O3">
            <title>Reactivity in Pregnant Female Population</title>
            <description>Specimens collected from 203 pregnant females: 153 specimens collected from pregnant females with documented risk factors for HIV and 50 were surplus serum specimens collected pregnant females from a health clinic offering HIV testing. Spcimens from 55 of the pregnant females with risk for HIV infection were collected under a specimen collection protocol and tested with the investigational and FDA-licensed comparator assay during the study. The remaining specimens were obtained from specimen vendors and tested with the investigational HIV test.</description>
          </group>
        </group_list>
        <measure>
          <title>Architect HIV Combo Test Data for Reactivity of Architect HIV Combo in Increased HIV Risk Populations</title>
          <description>Reactivity was determined by the results of the Architect HIV Ag/Ab Combo assay and supplemental testing by HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.</description>
          <population>Final HIV status determined for specimens reactive by investigational assay and/or comparator by supplement testing algorithm. Supplemental testing involved HIV-1 Western blot, HIV-2 EIA, HIV-2 Western blot, HIV-1 p24 Antigen assay and HIV-1 RNA. HIV positive status determined by HIV-1 Western blot.</population>
          <units>Blood specimens</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="513"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HIV Ag/Ab Combo Reactive HIV Status Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Reactive HIV Status Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Nonreactive - HIV Status Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Ag/Ab Combo Nonreactive HIV Status Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622"/>
                    <measurement group_id="O2" value="424"/>
                    <measurement group_id="O3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Device adverse events were collected during the approximate 3 months of testing with Architect HIV Combo assay.</time_frame>
      <desc>Adverse event reporting for follow-up collection (3) and subject's with specimens collected/tested during study (635)were under separate specimens collection protocol. Not applicable for specimens collected and banked or obtained from specimen venders and provided to testing site by Abbott.</desc>
      <group_list>
        <group group_id="E1">
          <title>Architect HIV Ag/Ab Combo Specificity</title>
          <description>Specimens collected from specimen vendors or from specimen collection studies were tested with investigation HIV test.</description>
        </group>
        <group group_id="E2">
          <title>Architect HIV Ag/Ab Combo Sensitivity</title>
          <description>Specimens collected from specimen vendors or from specimen collection studies were tested with investigation HIV test.</description>
        </group>
        <group group_id="E3">
          <title>Architect HIV Ag/Ab Combo Reactivity</title>
          <description>Specimens collected from specimen vendors or from specimen collection studies were tested with investigation HIV test.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator (PI) must provide copy of any proposed publication/presentation at least 30 days prior to submission for sponsor review/approval. PI must incorporate changes as the sponosr requires in order to protect the sponsor's proprietary rights and interests. Sponsor may require the PI to include acknowledgement of sponosr's role in the study. PI may be requested to delay publication/presentation an extra 60 days to enable sponor to secure patent or other proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Kaesdorf, Associate Director Clinical Affairs</name_or_title>
      <organization>Abbott Diagnostic Division</organization>
      <phone>847-937-8702</phone>
      <email>barbara.kaesdorf@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

